Back to School 2005: Innovation & economics

Entering the second half of the decade, and a five full years after the genomics bubble popped, the biopharmaceutical industry and its financiers are beset with doubts about business models, the ability to raise money, the still slow pace of product development, and an increasingly hostile public policy environment.

This risks loss of faith in the reason for this industry to exist, which is to bring innovation to the bedside. Thus it's time to declare an end to the griping and talk about solutions. It is now imperative to rekindle faith in innovation all along the value chain...